Regulation S-K

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Friday, November 20, 2020 - 6:03pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Friday, November 20, 2020 - 6:03pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Thursday, November 19, 2020 - 3:07pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Thursday, November 19, 2020 - 3:07pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

GOGL – Third Quarter 2020 Results

Thursday, November 19, 2020 - 7:06am

Questions should be directed to:

Key Points: 
  • Questions should be directed to:
    The full report is available in the link below.
  • Matters discussed in this earnings report may constitute forward-looking statements.
  • The forward-looking statements in this report are based upon various assumptions.
  • This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Wednesday, November 18, 2020 - 3:15pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Wednesday, November 18, 2020 - 3:14pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering

Tuesday, November 17, 2020 - 10:27pm

The closing of the offering is expected to occur on or about November 20, 2020, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about November 20, 2020, subject to satisfaction of customary closing conditions.
  • The gross proceeds to Oncternal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters option to purchase additional common stock, are expected to be approximately $20.0 million.
  • The shares of common stock are being offered by Oncternal pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Forward-looking statements include statements regarding: the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Tuesday, November 17, 2020 - 3:11pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Tuesday, November 17, 2020 - 3:11pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.